Yale Cancer Center

Articles

Boosting ‘Natural Killer’ Cell Activity Could Improve Cancer Therapy

July 14th 2024

Natural killer cells hold promise for treating cancer; Yale researchers have found a way to overcome their main limitation.

Yale Cancer Center Experts Present New Research on Obesity, Tobacco, Evolution, and Early Onset Cancers at Leading Oncology Conference

April 9th 2024

Yale Cancer Center will share data for breakthrough and emerging cancer treatments at the AACR Annual Meeting.

Amer Zeidan, MBBS, MHS, Appointed Inaugural Chief of the Division of Hematologic Malignancies

March 25th 2024

Amer Zeidan, MBBS, MHS, has been appointed inaugural chief of the Division of Hematologic Malignancies at Yale Cancer Center.

Why a Targeted Therapy is Better Than Immunotherapy for Some Patients with Inoperable Non-Small Cell Lung Cancer

February 5th 2024

Non-small cell lung cancer, with an EGFR mutation, tends not to respond well to immunotherapy treatments, including durvalumab.

Immunotherapy for Metastatic Cancer on the Rise, Even Near End of Life

January 12th 2024

Although use of immunotherapy near the end of life has increased over time, a closer look at the benefit of this in those with advanced cancers is needed.

HPV Discovery Yields Breakthrough in Understanding Protein Activity

October 17th 2023

A new study led by Yale scientists shows that the activity of a portion of a human papillomavirus protein does not depend on its amino acid sequence or composition.

Yale Cancer Center and Smilow Cancer Hospital Physicians and Scientists Presenting Latest Advances at 2023 ASCO Annual Meeting

May 24th 2023

Yale Cancer Center and Smilow Cancer Hospital scientists and clinicians will present new research at the 2023 Annual Meeting of the American Society of Clinical Oncology, June 2nd to June 6th at McCormick Place in Chicago, Illinois.

Study Finds Large Gap in Breast Cancer Treatment Recommendations for Patients Aged 70 vs 69

February 8th 2023

Age-based heuristics can lead to large differences in breast cancer treatment based on small differences in chronologic age, according to a new analysis of more than 500,000 patient records.

Barbara Burtness Named Chief Translational Research Officer for Yale Cancer Center and Smilow Cancer Hospital

December 9th 2022

Barbara Burtness, MD, has been named Chief Translational Research Officer for Yale Cancer Center and Smilow Cancer Hospital and Associate Cancer Center Director for Translational Research for Yale Cancer Center.

Oncology Therapy at the End of Life: Have We Missed the Mark?

November 3rd 2022

Continued treatment for patients with cancer near end of life delays conversations about goals of care and hospice enrollment, escalates costs, and may adversely affect the quality of care patients receive.

Yale Research Reveals “Biologically Older” Tissue in Patients with Breast Cancer

June 20th 2022

An analysis by Yale Cancer Center researchers identified accelerated genetic aging in breast tissue adjacent to breast cancer tumors.

Yale Scientists Develop Precision Medicine Approach to Metabolic Therapy for Breast Cancer

June 10th 2022

Scientists at Yale Cancer Center have found that patients with breast cancer and high levels of insulin in the blood may be responsive to metabolism-targeting treatments, which in turn may improve the effectiveness of subsequent chemotherapy treatments.

Combination Immunotherapy Improves Outcomes for Patients with Non-small Cell Lung Cancer

May 20th 2022

The phase 2 clinical trial of a multi-center study known as the COAST clinical trial has demonstrated improved outcomes using immunotherapy combinations for patients with unresectable stage III non–small cell lung cancer.

Yale Findings Broaden the Repertoire of Cancer-Relevant Genes

May 11th 2022

Following an analysis of over 12,000 human genes, research from Yale Cancer Center indicates there is cancer-relevant importance in a much larger proportion of human genes than current cancer research models suggest.

Yale Scientists Discover a New Pathogenic Mechanism in Hematological Malignancies

April 22nd 2022

Scientists at Yale Cancer Center have discovered new consequences of specific gene mutations that play a role in the development of myelodysplastic syndromes and acute myeloid leukemia.

‘Decision Switch’ Discovered in Mutations Linked to Common Brain Tumor

April 8th 2022

Researchers at the Yale Cancer Biology Institute have clarified the role of a recurring cancer-associated tumor mutation in glioblastoma multiforme, the most common and most aggressive type of malignant brain tumor.

Yale Cancer Center and School of Public Health Receive Grant to Study Lifestyle Intervention in Women with Ovarian Cancer

April 6th 2022

The National Cancer Institute recently awarded Yale Cancer Center and Yale School of Public Health a new U01 cooperative agreement grant to support research into the impact of diet and exercise for women with ovarian cancer.

New Class of Oncogenic Fusions Revealed in Lung and Pancreatic Cancer

March 24th 2022

A Yale Cancer Center research team has identified novel oncogenic gene fusions in lung and pancreatic cancer, as well as sarcoma. The fusions involve RASGRF1 (an activator of RAS signaling) and promote cellular changes leading to tumor development.

Yale Cancer Center Scientists Create Next-Generation CRISPR Tool to Aid Gene Editing

March 18th 2022

New research led by Yale Cancer Center shows the creation of a next-generation CRISPR-Cas9 “off-switch” and precision tool to aid safe gene editing therapeutics in patients.

Yale Cancer Center Annual Conclave Awards Presented

March 7th 2022

Yale Cancer Center held its annual Conclave award ceremony virtually on February 15 to celebrate scientific and caregiver accomplishments in 2021